Phase II study of everolimus in metastatic urothelial cancer

OBJECTIVE: To assess the efficacy and tolerability of everolimus in advanced urothelial carcimoma (UC). PATIENTS AND METHODS: The present study comprised a single-arm, non-randomized study in which all patients received everolimus 10 mg orally once daily continuously (one cycle = 4 weeks). In total,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Milowsky, Matthew I., Iyer, Gopa, Regazzi, Ashley M., Al-Ahmadie, Hikmat, Gerst, Scott R., Ostrovnaya, Irina, Gellert, Lan L., Kaplan, Rana, Garcia-Grossman, Ilana R., Pendse, Deepa, Balar, Arjun V., Flaherty, Anne Marie, Trout, Alisa, Solit, David B., Bajorin, Dean F.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4020005/
https://ncbi.nlm.nih.gov/pubmed/23551593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2012.11720.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars